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PLATELETS AND THROMBOPOIESIS
An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human
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The platelet P2Y12 purinoceptor (P2Y12R),
which plays a crucial role in hemostasis,
undergoes internalization and subse-
quent recycling to maintain receptor re-
sponsiveness, processes that are essen-
tial for normal platelet function. Here, we
observe that P2Y12R function is compro-
mised after deletion or mutation of the
4 amino acids at the extreme C-terminus
of this receptor (ETPM), a putative
postsynaptic density 95/disc large/zonula
occludens-1 (PDZ)–binding motif. In cell
line models, removal of this sequence or
mutation of one of its core residues
(P341A), attenuates receptor internaliza-
tion and receptor recycling back to the
membrane, thereby blocking receptor re-
sensitization. The physiologic signifi-
cance of these findings in the regulation
of platelet function is shown by identifica-
tion of a patient with a heterozygous
mutation in the PDZ binding sequence of
their P2Y12R (P341A) that is associated
with reduced expression of the P2Y12R on
the cell surface. Importantly, platelets from
this subject showed significantly compro-
mised P2Y12R recycling, emphasizing the
importance of the extreme C-terminus of
this receptor to ensure correct receptor
traffic. (Blood. 2011;118(20):5641-5651)
Introduction
ADP plays a central role in platelet activation by acting as a
released autocrine mediator in platelet responses to other agonists.
ADP activates 2 platelet G protein–coupled receptors (GPCRs),
P2Y1 and P2Y12, which couple, respectively, to Gq and Gi-
mediated pathways, and synergize to induce full platelet aggrega-
tion responses to ADP.1,2 Interaction of ADP with P2Y1 leads to
mobilization of intracellular calcium and activation of Rho kinase,
resulting in platelet shape change and an initial wave of rapidly
reversible aggregation. In contrast, ADP stimulation of P2Y12 is
associated with adenylyl cyclase inhibition and PI3K activation,
resulting in sustained aggregation in synergy with the P2Y1
receptor (P2Y1R). Activation of both receptors is required for a full
aggregation response to ADP.3
Recent work from our laboratory has shown that P2Y12
receptor (P2Y12R) responsiveness is rapidly and reversibly
modulated in human platelets.4 On prolonged exposure to
agonist, the responsiveness of P2Y12R, in human platelets,
decreases because of receptor desensitization5 and subsequent
internalization.6 In cell lines P2Y12Rs are regulated in a
G protein–receptor coupled kinase (GRK)–dependent manner,5
leading to their rapid recruitment to clathrin-coated pits (CCPs)
in an arrestin-dependent manner.7 The receptors are subse-
quently internalized and then recycled back to the cell surface
after receptor dephosphorylation.4 This internalization and
subsequent receptor recycling is required for the rapid resensiti-
zation of P2Y12R function in human platelets.4
Many GPCRs possess specific cytoplasmic sequences required
for efficient trafficking of the receptor into either lysosomal or
recycling pathways.8-10 In this study we have examined the
importance of the C-terminus of the P2Y12R in regulating these
dynamic regulatory and trafficking processes. Given the impor-
tance of this receptor for platelet activation in normal hemostasis
and in the pathophysiology of disorders such as coronary heart
disease,2 the understanding of how P2Y12R function is regulated is
essential for the improvement of existing antiplatelet agents and the
development of new therapeutic strategies.11
In this study, we demonstrate for the first time the critical
importance of a putative postsynaptic density 95/disc large/zonula
occludens-1 (PDZ)–binding motif at the extreme C-terminus of the
P2Y12R (ETPM) for correct receptor traffic and function by
expression in an immortalized cell line. Further, we report the
identification of a subject with a P341A mutation within the
PDZ-binding motif of their P2Y12R that both leads to reduced
receptor expression on the platelet surface and compromises
receptor traffic.
Methods
DMEM/F12 media, Lipofectamine 2000, and FBS, anti-hemagglutinin
(HA) mAb (HA-11), and goat anti–mouse fluorescein-conjugated second-
ary Ab were purchased from Invitrogen. Complete protease inhibitor tablets
and rhodamine-conjugated mouse monoclonal anti-HA Ab were from
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Roche. The anti-phosphothreonine Ab was from Cell Signaling Laborato-
ries. The P2Y12R-specific Ab, directed to the extracellular surface
N-terminus of the receptor, was from Imgenex. Radiochemicals were from
Perkin Elmer Life Sciences. All other reagents were from Sigma-Aldrich.
Construction of P2Y12R constructs
HA-tagged P2Y12 constructs were generated as previously described.5
Three C terminal tail truncation mutants of the HA-tagged P2Y12R were
engineered with the use of standard PCR techniques by introducing a stop
codon after K303, E339, and T320. Point mutants were obtained by PCR
amplification as for deletion mutants, with an antisense primer containing
the desired mutation and a site for the restriction enzyme XbaI at the 5 end,
to facilitate subsequent cloning in HA-pcDNA3. The PCR products and
pcNEO were digested with XhoI/XbaI, and, after purification, ligation was
undertaken with T4 ligase overnight at 4°C. Subsequent products were
transformed into DH5a cells, ampicillin-resistant colonies were amplified,
and the correct sequence was confirmed by sequencing.
Cell culture and transfection
Chinese hamster ovary (CHO)–K1 cells were cultured in DMEM/F-12 (50:
50) medium, 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin.
Stably transfected cells were cultured in the above medium supplemented
with 600 g/mL geneticin as previously described.7 Surface receptor
expression of wild-type and mutant receptor constructs was assessed by
radioligand binding as previously described with the use of [3H]-2MeSADP
(3 Ci [111 GBq]/mmol) and the P2Y12R antagonist AR-C69931MX to
measure specific binding.6
In transient transfections, cells were grown to 80%-90% confluence and
transfected with 0.5-10 g of DNA with the use of Lipofectamine
2000 according to the manufacturer’s instructions. Cell structure was
assessed throughout to ensure cells were healthy, and cell shape was
comparable with other studies that used these cells.12
Measurement of cAMP accumulation in CHO cells
Desensitization and signaling of P2Y12R responses in CHO cells were
measured as previously described.4 In desensitization/resensitization experi-
ments, cells were exposed to a desensitizing dose of ADP (10nM;
15 minutes) in the presence of the phosphodiesterase inhibitor
Ro201724 (250M). Apyrase (0.2 U/mL) was then added directly to each
well to promote receptor resensitization and incubated at 37°C (30 minutes)
to remove the desensitizing ADP. P2Y12R activity was assessed by adding
forskolin (1M) to cells in the absence or presence of ADP (0.01pM to
10M), and plates were incubated at 37°C for 10 minutes. Cyclic AMP
levels were subsequently assessed as previously described.4 Data are
expressed as the percentage of inhibition of forskolin-stimulated adenylyl
cyclase.
Measurement of receptor phosphorylation
Agonist-dependent P2Y12R phosphorylation was assessed as previously
described.6 After treatment with ADP (10M; 5 minutes) cells were placed
on ice and washed twice with ice-cold PBS. All subsequent procedures were
performed at 4°C unless otherwise stated. Cells were lysed and HA-tagged
receptor immunoprecipitated with the use of HA-11. Immune complexes
were then isolated and eluted from beads by the addition of 20 L of
electrophoresis sample buffer. After fractionation by SDS-PAGE and
transfer to a nitrocellulose membrane, phospho-threonine levels were
assessed with an anti–phospho-threonine Ab. Receptor immunoprecipita-
tion was determined by reprobing membranes with a polyclonal anti-HA
Ab/HRP-conjugated anti–rabbit IgG and visualization by ECL. P2Y12R
expression was also confirmed with a P2Y12-specific Ab. The extent of
receptor phosphorylation was quantified by densitometric analysis of
resulting autoradiographs.
Internalization and immunofluorescence microscopy of
HA-P2Y12 in CHO cells
HA-tagged surface receptor loss was assessed by ELISA as described
previously.4,7 Cells were transiently transfected with pcDNA3 containing
arrestin-2-dominant-negative mutant (arr-2-DNM; arrestin-2 [319-418]).
Eps-15-dominant-negative mutant (Eps-15-DNM; E95-295) or dynamin-
dominant negative mutant (dyn-DNM; dynamin-K44A). After 24 hours of
transfection, cells were split into 24-well tissue culture dishes. Twenty-four
hours later, cells were incubated with DMEM/F12 containing apyrase
(0.1 U/mL) for 1 hour at 37°C, washed, and then challenged with DMEM
containing ADP (1nM to 1mM) for 0-60 minutes at 37°C. To induce
receptor recycling apyrase was added (0.2 U/mL) to remove ADP. Changes
in surface receptor expression were subsequently determined by an ELISA,
taking advantage of the HA-epitope tag, and expressed as either the
percentage of surface receptor or the percentage of the loss of surface
receptor with the background signal from pcDNA3-transfected controls
subtracted from all receptor-transfected values.
Cellular distribution of HA- or FLAG-tagged receptor in CHO cells was
assessed by immunofluorescence microscopy.7 Briefly, cells were grown on
poly-L-lysine–coated coverslips in 6-well plates. Twenty-four hours later,
receptor distribution was assessed with a primary HA-11 (1:200) and goat
anti–mouse fluorescein-conjugated secondary Ab (1:200) or a polyclonal
anti-FLAG Ab and goat anti–rabbit rhodamine-conjugated secondary Ab
(1:200). Coverslips were mounted with the use of Slow-Fade mounting
medium and examined by microscopy on a Leica SP5-AOBS confocal laser
scanning microscope attached to a Leica DM I6000 inverted epifluores-
cence microscope with phase-contrast and a Plan-Apo 63  1.40 NA oil
immersion objective.
Arrestin-2–green fluorescent protein (arrestin-2–GFP) and arrestin-3–
GFP redistribution was assessed as previously described.13 Briefly, arrestin-
transfected cells were grown on poly-L-lysine–coated coverslips. Receptor
distribution was assessed with a rhodamine-conjugated mouse monoclonal
anti-HA Ab (1:100). Cells were then washed 3 times with PBS, and
coverslips were mounted before imaging in a heated imaging chamber
through which media and drugs could be added. Cells were examined by
microscopy as described in the previous paragraph. All images were collected
on Leica TCS-NT software and processed with Adobe Photoshop CS3.
Coimmunoprecipitation experiments
After drug treatment, cells were washed twice with ice-cold PBS and lysed,
and coimmunoprecipitation experiments were performed as previously
described.7 Arrestin-2–GFP was detected by immunoblotting with a mono-
clonal anti-GFP Ab. Proteins were detected by ECL.
P2RY12 sequencing
The P2RY12 coding sequence was PCR amplified from genomic DNA as
3 overlapping fragments with the use of oligonucleotide primers designed
to incorporate universal M13-tails at the 5 end (primer sequences indicated
in supplemental Table 1, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). PCRs
contained 30 ng of genomic DNA in a final volume of 15 L of 1
ReddyMix Master Mix (ABgene Ltd) containing 3 pmoles of each primer
and 1.5 or 3.0mM MgCl2, depending on the fragment being amplified. PCR
products were purified with ExoSAP-IT for PCR Product Clean Up (GE
Healthcare) and sequenced on an automated ABI 3730 DNA capillary
sequencer. The P2RY12 1021C  G mutation was sought in other subjects
by restriction analysis with the use of HinfI.
Platelet function studies
Whole blood, anticoagulated with sodium citrate (3.8%), was immediately
centrifuged at 130g for 15 minutes to obtain platelet-rich plasma (PRP). A
subsequent centrifugation at 1050g for 15 minutes was done to obtain
platelet-poor plasma, which was used to set the 100% light transmission of
the instrument. PRP (450 L) was warmed at 37°C for 3 minutes, and
50 L of Luciferine Luciferase was then added. After 30 seconds agonist
was added. Platelet aggregation and secretion were performed on a
Chrono-Log LumiAggregometer with ADP (1-100M), collagen (3 g/mL),
and epinephrine (10M). Platelet aggregation and ATP secretion were
recorded for 3 minutes, and the maximum light transmission in this period
was measured.14 Basal, prostaglandin E2 (PGE2; 10M)– or forskolin
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(1M)–stimulated cAMP levels were assessed in the absence and presence
of ADP (1nM to 10M) in platelets as previously described.6
Radioligand binding in human platelets
To induce receptor internalization platelets were stimulated with ADP
(10M; 15 minutes) or vehicle alone. ADP was then removed by the
addition of 0.2 U/mL apyrase (15 minutes) to induce receptor recycling.
P2Y1 and P2Y12 surface receptor expression was subsequently determined
by ligand binding in fixed platelets as previously described.6
Experimental design and statistics
Data were analyzed by the iterative fitting program GraphPad Prism. Log
concentration-effect curves were fitted to logistic expressions for single-site
analysis, whereas t0.5 values for agonist-induced internalization were obtained
by fitting data to single exponential curves. Where appropriate, statistical
significance was assessed by Mann-Whitney U test or by 2-way ANOVA.
Results
Construction and stable expression of full-length and mutant
P2Y12R constructs
The goal of this study was to determine the functional significance
of the C-terminus of the P2Y12 R. We constructed a series of C-tail
deletion mutants of the P2Y12R (Figure 1A), removing the last 4 amino
acids, a putative PDZ ligand (E339stop), a large proportion of the C-tail
(T320stop), or the entire C-tail (K303stop), all tagged at their N-terminus
with HA. In addition we made a receptor construct containing a point
mutation in this putative PDZ ligand found at the extreme C-terminus of
this receptor (P341A) to disrupt the integrity of this motif. Receptor
constructs were stably expressed in P2Y12-null CHO cells. Ligand
binding studies with the P2Y receptor ligand [3H]-2MeSADP (Figure
1B) showed that each of these receptor mutants was expressed at the cell
surface at comparable levels to that of full-length receptor, with the
exception of the K303 stop mutant that failed to be expressed at the cell
surface. The lack of K303 stop surface expression was also confirmed by
immunofluorescent microscopy (data not shown). Agonist-dependent
activation of each of the other Gi-coupled P2Y12R mutants was
comparable to that of the full-length receptor (Figure 1C) as indicated by
inhibition of forskolin-stimulated adenylyl cyclase. Only the T320stop,
E339stop, and P341A variant P2Y12Rs were studied further.
The extreme C-terminus of the P2Y12R regulates agonist-
induced receptor desensitization
We have previously reported in both cell lines and platelets4 that
pretreatment with ADP promotes desensitization of P2Y12, whereas
removal of ADP with apyrase promotes a rapid resensitization of
Figure 1. Removal of the extreme C-terminus of the
P2Y12 receptor does not affect surface expression or
G protein coupling. (A) Sequence comparison of the
COOH terminus domains of the human P2Y12 receptor
constructs. Potential phosphorylation sites are in bold
and the PDZ ligand found at the extreme C-terminus of
the receptor is underlined. (B) Receptor levels were
measured in CHO cells stably expressing wild-type or
mutant receptor with the use of [3H]2MeSADP (0.1-
10M) in the presence of the P2Y12 receptor antagonist
AR-C69931MX (1M) to determine specific binding.
Data are expressed as specific binding of [3H]2MeSADP
(cpm) per milligram of protein and represent
means  SEMs of 5 independent experiments. (C) Ago-
nist (ADP; 0.01pM to 10M)–dependent inhibition of
forskolin (1M; 10 minutes)–stimulated adenylyl cyclase
activity was assessed in CHO cells stably expressing
wild-type and mutant receptor constructs. Data are ex-
pressed as percentage inhibition of forskolin-stimulated
adenylyl cyclase and represent means  SEMs of
5 independent experiments.
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full-length P2Y12R, a result that was confirmed in this study in
stably transfected CHO cells for inhibition of cAMP formation by
forskolin (Figure 2A). Importantly, desensitization of both E339stop
and T320stop was reduced by  50% (P  .05), indicating that the
last 4 amino acids at the extreme C-terminus of this receptor are
required for efficient P2Y12R desensitization (Figure 2B). Given
that GRK-dependent phosphorylation has been shown to regulate
P2Y12R desensitization,7 we examined the ability of these receptor
constructs to be phosphorylated (Figure 2C). Agonist-induced
phosphorylation of E339stop and T320stop was reduced by  75%
(P  .05) compared with the full-length receptor as shown in a
representative experiment (Figure 2C) and confirmed by densitomet-
ric analysis of multiple blots (Figure 2D). Given that T340 is the
only phospho-acceptor site in the last 4 amino acids, our results
suggest that phosphorylation of this residue is probably required
for agonist-induced P2Y12R desensitization, although the possibil-
ity that the extreme C-terminus of this receptor may interact with a
regulatory kinase cannot be excluded. The desensitization and
phosphorylation of the P341A construct meanwhile was not
significantly attenuated, indicating that the integrity of the PDZ
domain is unlikely to be required for receptor phosphorylation or
desensitization. Importantly, however, as was the case for the
E339stop and T320stop receptors, P341A did not resensitize after
agonist removal (Figure 2A), indicating that the PDZ ligand is
required for effective receptor resensitization.
The PDZ ligand of the P2Y12R is required for effective
agonist-induced traffic
Receptor internalization and recycling are key regulators of
P2Y12R resensitization in both cell lines and human platelets.4
Importantly, P2Y12R internalization does not appear to affect the
degree of receptor desensitization. We therefore next sought to
determine whether receptor traffic was altered for these mutant
Figure 2. The extreme C-terminus of the P2Y12 recep-
tor is required for normal agonist-induced regulation
of receptor function. (A-B) P2Y12 desensitization and
subsequent resensitization were assessed by comparing
agonist (ADP; 10M)–dependent inhibition of forskolin
(1M; 10 minutes)–stimulated adenylyl cyclase activity
before (control) and after pretreatment with either ADP
alone (10nM; 15 minutes; desens on graph) or after
subsequent removal of desensitizing ADP with apyrase
(0.2 U/mL; 15 minutes; resens on graph). Data represent
means  SEMs of 6 independent experiments. (A) Raw
data are expressed as pmol cAMP/mg protein. (B) Data
are expressed as percentage of initial P2Y12 response.
*Statistical significance at P  .05 for data compared
with respective densitized wild-type control (Mann-
Whitney U test). #Statistical significance at P  .05 for
resensitized compared with respective resensitized con-
trol (Mann-Whitney U test). (C-D) Phosphorylation of
full-length and mutant HA-P2Y12 was assessed in CHO
cells stably expressing receptor constructs. Cells were
treated with ADP (10M; 5 minutes) or vehicle alone, and
HA-tagged receptors were immunoprecipitated from
membrane lysates and run on SDS-PAGE before trans-
fer to nitrocellulose membranes. Specific phosphorylated
bands between 50 and 75 kDa not present in vector-
alone pcNEO-transfected controls were subsequently
identified with a phosphothreonine-specific Ab. Similar
amounts of receptor immunoprecipitation were con-
firmed by reprobing membranes with a polyclonal anti-HA
Ab/HRP-conjugated anti–rabbit IgG and visualization by
ECL. Receptor immunoprecipitation was also confirmed
by reprobing with a P2Y12-specific N-terminal Ab. Data
are representative of 3 individual experiments. (C) Densi-
tometric analysis of 3 experiments was performed, and
data were expressed as fold increase over basal phos-
phorylation
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receptors. Making use of the N-terminal HA epitope–tagged
versions of wild-type and variant receptor constructs stably ex-
pressed in CHO cells, we were able to quantify the agonist-induced
surface receptor loss and subsequent recycling back to the cell
surface by ELISA4,7,15 and immunofluorescence microscopy4 as
previously described. Total surface receptor loss was attenuated for
all mutant receptors compared with the full-length receptor with
this attenuation of surface loss maintained after  8 hours of
agonist exposure (Figure 3A). This result shows that an intact PDZ
ligand is essential for normal internalization. Receptor recycling to
the cell surface was completely blocked with the E339stop, T320stop,
and P341A variant receptors, showing demonstrating a critical
role for the PDZ-binding domain in the return to the membrane
(Figure 3B).
Further analysis by immunofluorescence microscopy confirmed
that these variant receptors did not recycle efficiently to the cell
surface after internalization and that they were retained in an
intracellular sorting compartment (Figure 3C). In these experi-
ments we transiently coexpressed FLAG-tagged wild-type receptor
into cells stably expressing HA-tagged E339stop or P341A variant
receptors. After agonist exposure the mutant receptors colocalized
(shown in green) with wild-type receptor (shown in red; overlay in
yellow Figure 3C; ADP). However, after agonist removal E339stop
and P341A variant receptors remained retained in an intracellular
sorting compartment, whereas wild-type receptor efficiently re-
cycled back to the cell surface (Figure 3C; ADP/apyrase). There-
fore, the PDZ ligand of the P2Y12R appears to play a critical role in
regulating both receptor internalization and recycling to the
surface, directing receptor sorting.
The PDZ ligand of the P2Y12R is required for arrestin-
dependent internalization
We next sought to determine why receptor internalization and
traffic was attenuated in the variant P2Y12Rs lacking a functional
PDZ ligand (P341A or E339stop). P2Y12R internalization is arrestin
dependent with activation of P2Y12Rs leading to rapid recruitment
of arrestin-2 and arrestin-3 from cytosol to membrane in trans-
fected cell lines.7 Before agonist stimulation, arrestin-2–GFP
displayed a diffuse cytoplasmic distribution in CHO cells express-
ing each of the receptor constructs (Figure 4A). After the addition
of ADP (10M) to cells expressing wild-type P2Y12R, rapid
translocation of arrestin-2–GFP from cytosol to the membrane was
observed. In contrast, arrestin-2–GFP did not translocate in cells
expressing either P341A or E339stop. A similar series of observa-
tions were obtained in cells transfected with arrestin-3–GFP (data
not shown). We next undertook a series of coimmunoprecipitation
experiments to investigate possible arrestin-2/P2Y12R interaction
(Figure 4B). With the use of the HA epitope to immunoprecipitate
the receptor, we demonstrated coprecipitation of arrestin-2–GFP
with the wild-type P2Y12R, but not with T320stop, E339stop, or the
P341A mutant, after agonist addition (Figure 4B). Furthermore,
overexpression ( 5-fold over endogenous levels) of a dominant-
negative mutant form of arrestin-2 (319-418; arrestin-DNM)
selectively attenuated agonist-induced wild-type but not mutant
receptor internalization (Figure 4C). This arrestin mutant lacks the
receptor-binding region found in the endogenous protein and
competes with both wild-type arrestin-2 and arrestin-3 for clathrin
binding.16 Therefore, an intact PDZ ligand appears to be required
for arrestin/P2Y12R interaction and subsequent arrestin-dependent
receptor internalization.
The PDZ ligand of the P2Y12R is not required for clathrin-
dependent internalization
Because we have previously demonstrated that wild-type P2Y12R
internalizes through CCPs in a dynamin-dependent manner,7 we
next examined the ability of the P341A or E339stop variants to
undergo clathrin-dependent internalization. Eps-15–DNM blocks
CCP formation by disrupting the interaction between eps-15 and
the clathrin adaptor complex AP-2 essential for normal formation
of CCPs.17 Dynamin-DNM is deficient in its ability to bind GTP
and functions to inhibit dynamin-mediated scission of clathrin-
coated vesicles from the plasma membrane.18 As shown in Figure
4C, expression of either eps-15–DNM or dynamin-DNM strongly
inhibited ADP-induced (10M; 30 minutes) internalization of
wild-type and variant receptors. These results show that the variant
receptors can, like the wild-type receptor, internalize in a clathrin-
and dynamin-dependent manner.
The PDZ ligand of the P2Y12R is required for effective
agonist-induced traffic in human platelets
The studies in CHO cells transfected with wild-type and variant
constructs indicated the critical importance of the carboxyl-
terminus and specifically the PDZ ligand in regulating receptor
traffic and function. To corroborate this finding in platelets, and
hypothesizing that a loss in function of the C-terminal tail would be
associated with a mild bleeding tendency, we sought to identify
patients with naturally occurring mutations in the carboxyl-
terminus of the P2Y12R. In parallel to this work, we have been
searching for mutations in the P2Y12R in patients enriched for
bleeding.19 Given the similarities in bleeding symptoms between
patients with type 1 VWD and platelet-based bleeding disorders
and the growing evidence for locus heterogeneity in type 1 VWD,
we focused our attention on a cohort of patients with bleeding
symptoms and a diagnosis of type 1 VWD who had been recruited
previously to the European Molecular and Clinical Markers for the
Diagnosis and Management of Type 1 von Willebrand Disease
(MCMDM-1VWD) study.20 Phenotypic and genotypic characteriza-
tions of the MCMDM-1VWD cohort have confirmed the contribu-
tion of genetic loci outside of the VWF locus to the pathogenesis of
type 1 VWD.20 Indeed, investigation of a subgroup of this cohort
recently identified a novel P2RY12 gene defect in one of the index
cases who was enrolled in the study with a diagnosis of type
1 VWD and a VWF defect.19 Sequencing of the P2Y12 gene
(P2RY12) in the remaining index cases in this study identified a
single patient who was heterozygous for a C  G transversion at
nucleotide 1021 of the P2RY12 cDNA (	1 is the A of the initiator
ATG codon), which was predictive of a P341A substitution within
the P2Y12 PDZ ligand characterized above. The 1021C  G
transversion was not listed in the dbSNP database, and did not
occur among 100 healthy control subjects (200 alleles) recruited in
the same center as the patient or in publically available databases,
indicating that the alteration was unlikely to represent a novel
polymorphism in the general population. The patient, who had a
bleeding history consistent with the diagnosis of type 1 VWD
(bleeding severity score 
 1421) was not available for further
investigation. However, the mother of the patient, who was
reported to have normal VWF levels accompanied with mild
bleeding tendency (bleeding severity score
 421) and was heterozy-
gous for the P341A mutation, was available for investigation.
We initially examined surface expression of ADP receptors on
platelets from the subject with the P341A variant by ligand binding
with the use of [3H]-2MeSADP (100nM) in the presence of A3P5P
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Figure 3. Agonist-induced internalization and traffic is blocked after removal or mutation of the PDZ ligand on the extreme C-terminus of the P2Y12 receptor.
(A-B) CHO cells stably expressing either wild-type or mutant P2Y12 receptor were challenged with (A) ADP (10M; 0-480 minutes) to induce receptor internalization or with
(B) ADP (10M; 60 minutes) to induce receptor internalization then apyrase (0.2 U/mL) to remove ADP and to promote subsequent receptor recycling. Surface receptor loss
was subsequently assessed by ELISA as described in “Methods.” The data represent means  SEMs of 5 independent experiments. (C) CHO cells stably expressing
HA-tagged mutant receptor constructs were transiently transfected with FLAG-tagged wild-type P2Y12 receptor. Cells were preincubated with a monoclonal anti-HA or
polyclonal anti-FLAG Ab at 4°C for 1 hour. Subsequently, cells were incubated at 37°C for 60 minutes in the absence or presence of agonist (ADP; 10M). Cells were then
incubated with apyrase for (0.2 U/mL) for 60 minutes. Receptor localization was determined by immunofluorescence in fixed cells and was visualized with a monoclonal
fluorescein-conjugated or polyclonal rhodamine-conjugated secondary Ab. Groups of cells coexpressing wild-type receptor (red) with either E339stop (green) or P341A (green)
are shown in the absence of agonist (Basal), after agonist treatment (ADP), or after agonist removal (ADP/apyrase). E339stop or P341A P2Y12 receptor (green) retained in the
cells after agonist removal is clearly evident in the overlay. Data shown are representative of 3 independent experiments. Images were taken using a Leica SP5-AOBS confocal
laser scanning microscope attached to a Leica DM I6000 inverted epifluorescence microscope with phase-contrast and a Plan-Apo 63/1.40 NA oil immersion objective as
stated in “Internalization and immunofluorescence microscopy.”
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(1mM; Figure 5A) or AR-C69931MX (1M; Figure 5B) to distin-
guish either the P2Y1 or P2Y12 surface binding sites.4,7 Importantly,
there was a significant reduction in P2Y12 surface binding sites in
platelets (44.9%  5.5% decrease in Bmax) from the subject with
the P2Y12-P341A variant versus a healthy donor control that was
analyzed on the same day whose levels of P2Y12 surface expression
were consistent with previous reports from our laboratory.6 In
contrast P2Y1 surface receptor expression was unaltered. Western
blotting of platelet cell lysates with a P2Y12-specific Ab (Figure
2B) showed no difference in total levels of P2Y12R in platelets from
a healthy donor and the subject with the P2Y12-P341A variant
(Figure 5C). The specificity of this Ab to assess P2Y12R expression
was again confirmed in CHO cells stably expressing P2Y12R or
vector alone controls. Therefore, only surface and not total P2Y12
expression appears to be altered in the subject with the P341A
substitution compared with healthy donor controls, suggesting that
the receptor has become trapped in an intracellular compartment.
Interestingly, P2Y12R function appeared to be altered with
submaximal concentrations of ADP (0.1M), producing little
inhibition of PGE2-stimulated adenylyl cyclase (Figure 6A-B),
whereas healthy donor controls were able to produce a modest
increase in P2Y12R activity (Figure 6A-B). At higher concentra-
tions of ADP (1M) P2Y12R activity was similar in both the patient
and healthy donor controls (Figure 5A-B). Basal and PGE2-
stimulated cAMP levels were also comparable between the patient
and healthy donor controls (Figure 6A). Platelets from the subject
showed sustained aggregation and dense granule secretion, which
were similar to that of control platelets, in response to a range of
ADP concentrations (1-100M). Aggregation in response to colla-
gen (3 g/mL) and adrenaline (10M) was also similar to that of
control platelets, confirming the integrity of agonist-induced plate-
let activation in the subject.
Because the patient was unavailable for further study and to
determine whether the reduction in P2Y12R surface expression was
responsible for the reduction in receptor signaling at low concentra-
tions of ADP, we examined P2Y12R function in platelets where we
pharmacologically reduced receptor availability. In these experi-
ments we used 2 different concentrations of the P2Y12R antagonist
Figure 4. An intact PDZ-binding ligand is required for
arrestin- but not clathrin-dependent internalization
of the P2Y12 receptor. (A) Cells stably expressing
receptor constructs were transfected with arrestin-2–
GFP. Before imaging, coverslips were mounted in an
imaging chamber at 37°C. The initial diffuse cytoplasmic
distribution of arrestin-2–GFP is shown before agonist
stimulation (0 second). ADP (10M) was added, and the
redistribution of arrestin-2 was monitored in real time.
The images shown were collected at 10, 60, and 240 sec-
onds after agonist addition. Data shown are representa-
tive of 3 independent experiments. (B) Cells stably
expressing receptor construct were transiently trans-
fected with arrestin-2–GFP. Cells were stimulated with
ADP (10M; 5 and 10 minutes). Receptor was immuno-
precipitated from cell lysates with the use of an anti-HA
Ab (HA-11), and arrestin-2 association was assessed
with an anti-GFP Ab. Equal loading of arrestin-2–GFP
was confirmed in cell lysates taken before receptor
immunoprecipitation. As shown arrestin-2/receptor asso-
ciation was only found in cells expressing the full-length
P2Y12 purinergic receptor. Like E339stop and the P341A
variant, T320stop did not associate with arrestin (data not
shown). Data shown are representative of 3 independent
experiments. (C) Receptor-expressing cells were tran-
siently transfected with DNM forms of arrestin-2 (319-
418; arrestin-DNM), eps-15 (E95-295; eps-15–DNM),
dynamin (K44A; dynamin-DNM), or vector (pcDNA3)
alone. Cells were subsequently challenged with ADP
(10M; 30 minutes), and surface receptor loss was
assessed by ELISA. The data represent means  SEMs
of 7 independent experiments. *P  .05 compared with
respective pcDNA3 vector transfected controls (Mann-
Whitney U test).
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AR-C69931MX, either at 3nM, which in our hands it displaces
 50% of the P2Y radioligand [3H]-2MeSADP, or 1M, which
blocks all P2Y12 ligand binding (Figure 6C). The higher 1-M
concentration of AR-C69931MX as expected almost completely
blocked ADP-stimulated P2Y12 inhibition of PGE2-stimulated
adenylyl cyclase. Importantly, the lower concentration of
AR-C69931MX (3nM), which produces a reduction in P2Y12
surface availability comparable to that seen in the patient, only
inhibited ADP-stimulated P2Y12R activity at lower concentrations
of ADP (ie, 0.1M). At higher ADP concentrations ( 1M)
P2Y12R stimulation was maintained (Figure 6D). Therefore, simi-
lar to our patient studies partial reductions in P2Y12R surface
availability only attenuated ADP stimulation at submaximal
concentrations.
Because changes in levels of P2Y12 surface receptor expression
were evident (Figure 5C), we next examined if receptor traffic was
impaired in platelets from the subject with the P2Y12-P341A
variant (Figure 7). Consistent with our previous studies,4 platelets
from healthy donors showed a clear reduction in [3H]-2MeSADP
binding to both P2Y1 (Figure 7A,C) and P2Y12 (Figure 7B-C) after
pretreatment with ADP (10M; 10 minutes). Agonist-induced loss
of surface P2Y1 and P2Y12Rs were similar in platelets from the
subject with the P341A variant of P2Y12 (ADP on Figure 7C). This
was different to our findings in cell lines in which the P341A
variant stably overexpressed in CHO cells showed attenuated
receptor internalization. After lengthened periods of apyrase expo-
sure for 30 minutes (ADP/apyrase on Figure 7B) both the P2Y1 and
P2Y12 surface receptor levels returned to control levels as expected
in platelets from healthy donor patients.4 In contrast, platelets from
the subject with the P341A variant did not display rapid P2Y12R
recycling. P2Y1R traffic meanwhile was similar to that in healthy
donor platelets. Further studies with a larger group of healthy
donors also showed consistent recycling of P2Y12R back to the cell
surface after removal of ADP, whereas that of the patient was
blocked (Figure 7D). Therefore, in agreement with our cell line
studies, the P341A substitution within the PDZ ligand of the
P2Y12R significantly impaired correct receptor recycling back to
the membrane in human platelets.
Discussion
Here, we report for the first time in tissue of a human origin that the
integrity of a PDZ ligand is essential for normal protein function.
This was shown through studies characterizing the molecular
determinants regulating traffic of P2Y12 purinoceptors in human
platelets. Through the course of our studies we showed that the
presence of the PDZ ligand of the receptor regulated receptor traffic
both in transfected cell lines and most importantly in human
platelets. This receptor, which internalizes through clathrin-
mediated endocytosis in a GRK- and arrestin-dependent manner,7
was mistrafficked after removal or disruption of its PDZ ligand
leading to its retention in an endocytic-sorting compartment.
Importantly, this mistraffic blocked the ability of the receptor to
recycle back to the cell surface and hence blocked receptor
resensitization, a process essential for normal platelet purinoceptor
function.4 Critically, we have studied a human subject with a
naturally occurring mutation predicted to disrupt the PDZ ligand in
the P2Y12R. Platelets from this subject showed significantly
compromised P2Y12R traffic. To our knowledge this is the first
report of an identified mutation in the PDZ ligand of an endog-
enously expressed protein leading to an observable change in
protein traffic. This provides valuable confirmation ex vivo of the
physiologic significance of PDZ-mediated pathways.
P2Y12Rs play an essential role in ADP-induced platelet activa-
tion and are important pharmacologic targets in the treatment of
arterial thrombotic disease.2,11 Their functional regulation is there-
fore critical for the control of hemostasis and thrombosis.2,4 Our
studies have shown for the first time in human platelets that the
PDZ motif of this receptor is critically required for efficient
receptor recycling. We also show a reduction in surface versus total
receptor in platelets from the subject with the P341A variant that
we believe is because of the retention of receptor in intracellular
sorting compartments after platelet exposure to low levels of ADP
possibly released from damaged cells during their transit in the
vasculature. It may also be the case that P2Y12-P341A variant
expresses poorly at the cell surface in human platelets, although our
Figure 5. Expression of P2Y1 and P2Y12 receptors in platelets from a subject
with a heterozygous P2Y12 P341A substitution. (A-B) P2Y1 and P2Y12 surface
receptor levels were measured in fixed platelets from healthy donors (HDs) or from
the subject with a heterozygous P2Y12 P341A mutation (P341A) by displacement of
[3H]2MeSADP (1nM to 1M) by receptor antagonists for P2Y1 (A3P5P; 1mM) and
P2Y12 (AR-C69931MX; 1M), respectively. Data are expressed as [3H]2MeSADP
binding (DPM) and represent means  SEMs. *Statistically significant reduction in
P2Y12 binding levels at P  .05 for data compared with respective control data
(Mann-Whitney U test). (C) Total P2Y12 receptor expression was assessed by
immunoblotting with a P2Y12-specific Ab in cell lysates from HDs or P341A patient
platelets and CHO cells stably expressing full-length P2Y12 or pcNEO control. Data
shown are representative for 3 independent experiments. Densitometric analysis of
3 experiments was performed and, when data were expressed as fold increase over
HD values of 1.1, 0.9 and 1.1 were obtained, indicating no change.
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cell line studies indicate that this receptor appears to be exported
and inserted efficiently into the cell membrane.
Although the mild bleeding symptoms that have been associ-
ated with P2Y12 deficiency are usually recessively inherited,
heterozygous defects have also been reported in patients with a
hemorrhagic diathesis.22-24 Our recent study of a novel heterozy-
gous P2Y12 defect and its association with bleeding in a family with
type 1 VWD supports a contribution from other loci to the bleeding
tendency in patients with type 1 VWD and provides further
evidence for locus heterogeneity in this disorder.19 In this present
study we have identified a patient with type 1 VWD and heterozy-
gous for the P341A mutation. Although this patient (bleeding
Figure 6. P2Y12 receptor signaling in platelets from a
subject with a heterozygous P2Y12 P341A substitution.
(A-B) P2Y12 receptor signaling was measured in platelets
from healthy donors (HDs) or from the subject with a
heterozygous P2Y12 P341Amutation (P341A). P2Y12 recep-
tor signaling was assessed by comparing agonist (ADP; 0.1
and 1M)–dependent inhibition of PGE2 (10M; 5 minutes)–
stimulated adenylyl cyclase activity. (A) The raw data from
the patient and HD1 are expressed as pmol cAMP/
1 109 platelets. (B) Data from the patient and a range of
HDs are expressed as percentage of inhibition of PGE2-
stimulated adenylyl cyclase. (C-D) The result of a partial
reduction in P2Y12 receptor availability was further investi-
gated. (C) Displacement of the P2Y-specific ligand [3H]-
2MeSADP by ARC69931. Fixed platelets were incubated
with [3H]2MeSADP (100nM), and bound ligand was dis-
placed by increasing concentrations of the P2Y12 receptor
antagonist AR-C69931MX (0.1nM to 10M). Data are ex-
pressed as total 3H-2MeSADP binding (DPM) and represent
means SEMs of 3 independent experiments. From this
data 2 concentrations of AR-C69931MX were used: 3nM,
which displaces  50% of specific ligand binding, and a
maximal concentration of 1M. (D) Inhibition of ADP-
stimulated P2Y12 receptor activity by antagonism with differ-
ent concentrations of AR-C69931 MX in human platelets.
Agonist (ADP; 1nM to 10M)–dependent inhibition of PGE2
(10M; 5 minutes)–stimulated adenylyl cyclase activity was
assessed in the absence and presence of AR-C69931 MX
(3nM and 1M). Data are expressed as the percentage of
inhibition of PGE2-stimulated adenylyl cyclase and represent
means SEMs of 3 independent experiments. Pretreat-
ment with 3nM AR-C69931 MX shifts the EC50 for ADP from
95 8nM in the absence and 380 13nM in the presence
of antagonist (P .05, Mann-Whitney U test).
Figure 7. Reduced recycling of P2Y12 receptors in
platelets from a subject with a heterozygous P2Y12
P341A mutation. Platelets from healthy donors (HDs) or
from the subject with a heterozygous P2Y12 P341A mutation
(P341A) were exposed to ADP (10M; 10 minutes) to pro-
mote receptor internalization (ADP on graph) and then
apyrase (0.2 U/mL; 30 minutes) to promote receptor recy-
cling (ADP/apyrase on graph). P2Y1 and P2Y12 surface
receptor levels were subsequently measured in fixed plate-
lets with the use of [3H]-2MeSADP (100nM) in the presence
of either the P2Y1 receptor antagonist A3P5P (1mM) or the
P2Y12 receptor antagonistAR-C69931MX (1M). (A-B) Data
are expressed as specific [3H]-2MeSADP binding to the P2Y1
and P2Y12 receptors, respectively (DPM). (B) #Statistical
significance at P .05 for data compared with basal HD1
control. *Statistical significance at P .05 for data compared
with respective resensitized HD1 control (Mann-Whitney
U test). (C) Data are expressed as the percentage of surface
receptor and represent means SEMs. Statistical signifi-
cance at P .05 for data compared with respective resensi-
tized HD1 control (Mann-Whitney U test). (D) Data are
expressed as specific P2Y12 receptor binding (DPM) in
human platelets and represent data from 6 healthy donors
and the patient (P341A) in basal, ADP (10M; 10 minutes)
stimulated to promote receptor internalization, and then
apyrase (0.2 U/mL; 30 minutes) to promote receptor recy-
cling (ADP/apyrase on graph) conditions.
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severity score 
 1421) was not available for further investigation,
the mother of the patient, who has normal VWF levels accompanied
with mild bleeding tendency (bleeding severity score 
 421), was
studied.
Studies on this subject showed a significant decrease in surface
P2Y12R coupled with a significant impairment of P2Y12R recy-
cling. These changes are accompanied with a reduction in respon-
siveness to submaximal concentrations of ADP, although platelet
aggregation and secretion after acute periods of maximal concentra-
tions of ADP stimulation are not different from controls. We
hypothesize that the failure of the P341A variant to recycle may
lead to an impairment in ADP responsiveness after more
prolonged periods of platelet activation, such as seen in the
growing thrombus.25,26 Previously, we have shown that, in order
for P2Y12Rs to resensitize after agonist-induced desensitization,
they need to internalize and then subsequently recycle back to
the cell surface.4 Any attenuation of receptor internalization
could lead to an increased prevalence of desensitized receptors
remaining on the cell surface, whereas the lack of recycling
would prevent any resensitized receptor returning to the cell
surface. Therefore, P2Y12R internalization and recycling are
processes critical for maintenance of receptor responsiveness in
platelets. Our cell line studies (Figure 2A) show that the
responsiveness of the P2Y12-P341A mutant does not resensitize
after agonist-induced desensitization. Given that continuous
ADP signaling is required for thrombus stability,25,26 we there-
fore speculate that the effect on signaling produced by the
blockade of P2Y12-P341A resensitization could affect on throm-
bus growth. Such a reduction in P2Y12R function may explain
the mild bleeding symptoms seen in the heterozygous carrier of
the P341A variant, although without further more detailed
studies we cannot conclude that this mutation is causative. A
more clear understanding of how the processes and timing of
P2Y desensitization and subsequent resensitization link with
thrombus formation, possibly provided by in vivo mouse
thrombus formation models, is required to fully understand their
effect. Interestingly, the P341A variant was associated with a
reduction in responsiveness to submaximal concentrations of
ADP. Our studies suggest that this reduction may reflect changes
in surface receptor expression seen with the P341A variant
because we can replicate our findings when we partially reduce
surface receptor levels with the use of P2Y12R antagonists.
Importantly in CHO cells transfected with the P341A variant
agonist-dependent activation of the P341A receptor was similar
to that of the wild-type receptor, indicating no obvious change in
receptor/G protein coupling. Unfortunately, detailed further
analysis examining the P341A variant in this patient and its
relevance to whole platelet function, especially at these submaxi-
mal concentrations of ADP or after repeated ADP challenge, is
not possible at this time.
Many GPCRs express C-terminal type I, type II, and type III
PDZ ligands (see recent review including bioinformatic search10)
with PDZ domain–containing proteins having established roles
in receptor traffic, localization, and assembly of signaling
complexes. For example, the 2AR has a C-terminal DSLL
motif that conforms to a type I PDZ ligand, which controls
receptor recycling.27 A type I PDZ ligand is also found in the
1AR and is capable of promoting PDZ-domain interactions and
receptor recycling.28 In addition to C-terminal PDZ ligands, one
study has indicated that an internal PDZ ligand present in the
ETA endothelin receptor C-tail can regulate receptor recycling.29
Our study has also shown that the C-terminal ETPM motif of the
P2Y12R, a type I PDZ motif, is required for receptor recycling.
Deletion or mutation of this sequence leads to the accumulation
of the receptor in an intracellular sorting compartment and
blockade of receptor recycling. Interestingly, the PDZ-
dependent recycling of the 2AR has recently been shown to be
regulated by its interaction with sorting nexin 27.30 We have as
of yet failed to identify a similar endocytic sorting protein
binding partner that can regulate the PDZ-dependent recycling
of the P2Y12R, although studies are ongoing. In addition to
recycling, PDZ ligands have been implicated in regulating
endocytosis of certain GPCRs.9,10 In our study, disruption or
removal of the PDZ ligand slowed down the internalization of
the receptor in CHO cells and blocked the ability of the receptor
to interact with arrestin. Our previous studies have shown that
receptor phosphorylation by GRKs regulates arrestin-dependent
P2Y12R internalization.7 Interestingly, studies in arrestin-2/
mice have suggested that arrestin-2 may play a role in thrombus
formation in vivo,31 although arrestin-dependent P2Y12R inter-
nalization was not investigated in these mice. In order for
arrestins to effectively interact with a GPCR they are believed to
recognize 2 binding sites on receptors: one that is shown on
agonist binding and a second that is shown on phosphoryla-
tion.32 The stability of arrestin/receptor association requires
receptor phosphorylation, although initial recruitment appears
to require an agonist-induced conformational change in receptor
structure. In our studies receptor phosphorylation and desensiti-
zation were significantly attenuated after removal of the PDZ
motif but were unaffected in the P341A variant. These data
suggest that either an interaction of this PDZ motif with a
regulatory kinase or phosphorylation of T340 found within this
PDZ motif is required for receptor phosphorylation, thereby
enhancing arrestin interaction. Interestingly, although the recom-
binant P341A variant was still phosphorylated, its ability to
interact with arrestin was lost. Therefore, the integrity of this
PDZ motif also appears to be required for arrestin interaction in
CHO cells. In addition, the P341A variant still desensitized, in
the absence of arrestin interaction, indicating that, although
arrestin is required for effective rapid internalization, it is not
required for the desensitization P341A variant.
Importantly, after mutation or removal of the PDZ ligand, the
P2Y12R was still able to undergo clathrin-dependent internaliza-
tion. A number of GPCRs, including the P2Y1R, have been
shown to internalize via CCPs in an arrestin-independent
manner.7,8 For example, arrestin-independent clathrin-mediated
endocytosis of M3 muscarinic receptors requires  subunit-
dependent recruitment of tubulin,33 and 1B-adrenoceptors are
endocytosed through a clathrin-mediated pathway by direct
interaction of the receptor with the AP2 complex machinery.34
This may in part explain why in our platelet studies the
P2Y12-P341A still appeared to internalize. The internalization of
P2Y12-P341A in human platelets may, as seen in cell line
studies, also be slowed. Unfortunately, such detailed measure-
ments of surface receptor loss require significant amounts of
platelet material that are not available. The reduced surface
expression in P2Y12-P341A platelets may also contribute to the
perceived willingness of this receptor to internalize because any
agonist-induced changes in surface receptor will be more
apparent than that seen in cell lines that have a significant
receptor reserve.
In conclusion we show for the first time for a protein natively
expressed in human tissue that the integrity of a PDZ ligand is
critical for protein function. Future screens of patients with mild
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bleeding disorders may show further important information about
the critical importance of structural motifs for the maintenance of
protein–protein interactions in the context of human disease.
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